[Treatment of central serous chorioretinopathy with beta blockers].
On a group of 13 eyes the authors evaluate their experience with medicamentous treatment of central serous chorioretinopathy. For treatment they used the non-selective beta-blocker Trimepranol, 2 x 5 mg/day. They found that in 11 eyes, in 84.6% cases, adherence of the ablated neuroepithelium of the macula occurred latest within four months of treatment, in two eyes (15.4%) this therapeutic dose did not lead to remission of the disease even after four months of treatment and the condition was evaluated as failure of treatment. The authors conclude that a therapeutic dose of Trimepranol of 2 x 5 mg/day is not a reliable therapeutic solution of central serous chorioretinopathy.
Chrapek
O
O
Ocní klinika FN a LF UP, Olomouc.
Spacková
K
K
Rehák
J
J
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use*; D000328:Adult; D015862:Choroid Diseases / Q000188:drug therapy* / Q000503:physiopathology; D005260:Female; D006801:Humans; D008297:Male; D014290:Metipranolol / Q000627:therapeutic use*; D012164:Retinal Diseases / Q000188:drug therapy* / Q000503:physiopathology; D014792:Visual Acuity
D000319:Adrenergic beta-Antagonists; D014290:Metipranolol